Barcelona

• A Phase 2, randomized, multicenter, open-label neoadjuvant study evaluating zanidatamab in combination with chemotherapy in participants wit … Recruiting
  2025-523204-68-00 4 2026-03-25 HER2-positive breast cancer
• A study to investigate efficacy, safety, immunogenicity, and pharmacokinetics of GSK3862995B following repeat doses in participants with bro … Recruiting
  2025-522892-27-00 4 2026-03-21 Bronchiectasis
• Studies testing Ziftomenib together with standard treatments in adults with newly diagnosed acute myeloid leukemia (AML) that has specific g … Recruiting
  2025-521314-25-00 5 2026-03-19 NPM1-m and KMT2A-r Acute Myeloid Leukemia
• ROSETTA Breast-01: The effects and safety of pumitamig in patients with triple-negative breast cancer Recruiting
  2025-521884-12-00 5 2026-03-19 First line triple-negative breast cancer (TNBC)
• EMPEROR: A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen (STK-001) in Patients with Dravet Syndrome Recruiting
  2024-519555-28-00 5 2026-03-18 Dravet syndrome
• A Phase I Study of BMS-986497 alone or in combination with Azacitidine (Aza) and Azacitidine plus Venetoclax (AZA+VEN) in relapsed or refrac … Recruiting
  2024-519537-29-00 1 2026-03-13 Acute Myeloid Leukemia and Myelodysplastic Syndrome
• MP: ADAPT Forward - Master protocol of a platform study to evaluate the safety and efficacy of multiple regimens in participants with Myasth … Recruiting
  2025-522492-28-00 4 2026-03-13 AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis,
• Trial of T-DXd Versus SoC Chemotherapy as Adjuvant Treatment in Endometrial Cancer Recruiting
  2024-519444-33-00 5 2026-03-12 HER2-expressing endometrial cancer (IHC 3+/2+)
• Visugromab, nivolumab and lenvatinib compared to double placebo and lenvatinib in unresectable or metastatic hepatocellular carcinoma post a … Recruiting
  2025-520675-86-00 4 2026-03-10 Unresectable or Metastatic Hepatocellular Carcinoma and Compensated Li
• A study to learn if DM199 drug is safe and whether it works better than placebo for treating acute ischemic stroke Recruiting
  2024-513911-28-00 10 2026-03-04 Acute Ischemic Stroke
• A Study to assess the Safety, Tolerability and effect of RO7673396 when used alone as well as with other cancer medications in participants … Recruiting
  2024-519622-20-00 1 2026-02-27 Advanced Solid Tumors Harboring RAS Mutation(S)
• A Phase 1 Study of AJ1-11095 in Adults with Myelofibrosis Failed by a JAK2 Inhibitor Recruiting
  2025-522033-64-00 1 2026-02-26 Myelofibrosis
• A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder Recruiting
  2025-523202-32-00 5 2026-02-26 Major Depressive Disorder
• A Study of the Efficacy and Safety of Danicamtiv in Participants with Symptomatic Genetic and Familial Dilated Cardiomyopathy. Recruiting
  2025-522553-19-00 10 2026-02-25 Symptomatic genetic and familial dilated cardiomyopathy.
• A study to investigate safety, tolerability, pharmacokinetics, and pharmacodynamics of surovatamig in adult participants with rheumatoid art … Recruiting
  2025-522273-10-00 3 2026-02-24 Systemic Lupus Erythematosus
• First-in-Human Study of RO7812653 Recruiting
  2025-522101-37-00 1 2026-02-17 Early Symptomatic Alzheimer’s Disease (eAD), (Mild Cognitive Impairmen
• A phase 3 efficacy and safety study of fosmanogepix for the treatment of adult patients with invasive mold infections Recruiting
  2024-516216-16-00 5 2026-02-13 Invasive mold infections caused by Aspergillus spp., Fusarium spp., Lo
• PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAMIZESTRANT PLUS RIBOCICLIB IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE (HR+) BREAST C … Recruiting
  2024-520027-88-00 4 2026-02-12 Patients with hormone receptor-positive (HR+) breast cancer
• A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of Trepostini … Recruiting
  2025-521558-40-00 5 2026-02-12 Pulmonary Hypertension Associated with Interstitial Lung Disease
• A clinical study of new treatments given with enfortumab vedotin and pembrolizumab in people with urothelial cancer (MK-3475-04D) Recruiting
  2025-522253-19-00 9 2026-02-11 Urothelial carcinoma
• A PK study to compare JPB898 (proposed nivolumab biosimilar) and US-licensed Opdivo® in participants with resected stage IIB, IIC, or III me … Recruiting
  2025-521919-39-00 3 2026-02-10 Resected stage IIB, IIC, or III melanoma requiring adjuvant treatment
• A Phase 1/2 study of ALXN2350 in adult participants with BAG3-associated dilated cardiomyopathy Recruiting
  2024-519674-40-00 7 2026-02-05 BAG3 Mutation Associated Dilated Cardiomyopathy
• A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRES … Recruiting
  2025-522170-36-00 5 2026-02-03 Diabetes Mellitus, Type 1
• A study of gilteritinib in adults with advanced ALK-positive non-small cell lung cancer (NSCLC) Recruiting
  2025-522398-12-00 3 2026-01-30 Locally advanced or metastatic NSCLC

Showing 337–360 of 3,391 trials